NVS Novartis AG

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549

 

SCHEDULE TO

 

Tender Offer Statement under Section 14(d)(1) or 13(e)(1)
of the Securities Exchange Act of 1934 

(Amendment No. 13)

 

MORPHOSYS AG 

(Name of Subject Company (Issuer))

 

NOVARTIS BIDCO AG 

an indirect wholly owned subsidiary of

 

NOVARTIS AG 

(Name of Filing Persons (Offerors))

 

Ordinary Shares, no Par Value 

(Title of Class of Securities)

 

617760202 

(CUSIP Number of Class of Securities)

 

Karen L. Hale
Chief Legal Officer
Novartis AG
Lichstrasse 35
CH-4056 Basel
Switzerland
Telephone: +41-61-324-1111
Fax: +41-61-324-7826 

(Name, Address, and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of Filing Persons)

 

With a copy to:

 

​

Jenny Hochenberg Freshfields Bruckhaus Deringer US LLP 601 Lexington Ave. New York, NY 10022 Telephone: +1 646 863-1626

​

​

Doug Smith Freshfields Bruckhaus Deringer LLP 100 Bishopsgate London EC2P 2SR United Kingdom +44 20 7936 4000

​

 

Check the appropriate boxes below to designate any transactions to which the statement relates:

 

x

third-party tender offer subject to Rule 14d-1.

¨

issuer tender offer subject to Rule 13e-4.

¨

going-private transaction subject to Rule 13e-3.

¨

amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer: ¨

 

If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:

 

¨

Rule 13e-4(i) (Cross-Border Issuer Tender Offer)

¨

Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)

 

 

This Amendment No. 13 (this “Amendment”) amends and supplements the Tender Offer Statement on Schedule TO filed with the Securities and Exchange Commission (the “SEC”) on April 11, 2024 (together with any amendments and supplements hereto, the “Schedule TO”) by Novartis AG, a stock corporation organized under the Laws of Switzerland (“Novartis”) and Novartis BidCo AG, a stock corporation organized under the Laws of Switzerland and an indirect wholly owned subsidiary of Novartis AG (the “Bidder” and, together with the Novartis, the “Filing Persons”). The Schedule TO relates to the voluntary takeover offer (the “Takeover Offer”) by the Bidder to purchase all no-par value registered shares (the “MorphoSys Shares”) in MorphoSys AG (“MorphoSys”), including the MorphoSys Shares represented by American Depositary Shares (“MorphoSys ADSs”), pursuant to a Business Combination Agreement, dated as of February 5, 2024, among MorphoSys and the Filing Persons. The terms and conditions of the Takeover Offer are described in the Offer Document, dated as of April 11, 2024, copy of which was filed as Exhibit (a)(1)(A) to the Schedule TO (the “Offer Document”), and, where applicable, the related Declaration of Acceptance or ADS Letter of Transmittal and the instructions thereto, copies of which were filed as Exhibits (a)(1)(B) and (a)(1)(E), respectively, to the Schedule TO.

 

This Amendment is being filed solely to amend and supplement items to the extent specifically provided herein. Except as otherwise set forth in this Amendment, the information set forth in the Schedule TO, including all exhibits thereto, remains unchanged and is incorporated herein by reference to the extent relevant to the items in this Amendment. This Amendment should be read together with the Schedule TO.

 

ITEMS 1 THROUGH 11.

 

Items 1 through 11 of the Schedule TO are hereby amended and supplemented by adding the following:

 

On May 24, 2024, the Bidder submitted a notification of major holdings to the Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht, BaFin) (the “Notification of Major Holdings”) announcing that the Bidder acquired 29,970,913 MorphoSys Shares, representing approximately 79.46% of the share capital and the voting rights, excluding treasury shares held by MorphoSys, as of May 23, 2024. The Notification of Major Holdings is filed hereto as Exhibit (a)(5)(T) and is incorporated herein by reference.

 

ITEM 12.  EXHIBITS.

 

Item 12 of the Schedule TO is hereby amended and supplemented by adding the following:

 

Exhibit		Description
(a)(5)(T)		Notification of Major Holdings of the Bidder, dated May 24, 2024.

 

 

SIGNATURES

 

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: May 24, 2024

 

	NOVARTIS BIDCO AG
	By:	/s/ David Quartner
		Name:	David Quartner
		Title:	As Attorney
	By:	/s/ Lukas Gilgen
		Name:	Lukas Gilgen
		Title:	As Attorney
	NOVARTIS AG
	By:	/s/ David Quartner
		Name:	David Quartner
		Title:	As Attorney
	By:	/s/ Lukas Gilgen
		Name:	Lukas Gilgen
		Title:	As Attorney

 

 

 

Exhibit (a)(5)(T)

 

Notification of Major Holdings

 

This form is for information purpose only. From 1 July 2020 on submission of a notification to BaFin and to the
company must be made electronically. The notification to BaFin has to be submitted by using BaFin’s MVP-Portal.

 

x Notification of Major Holdings or ¨ Correction of a notification of Major Holdings dated

 

1. Details of issuer
Name: MorphoSys AG	Legal Entity Identifier (LEI): 529900493806K77LRE72
Street, Street number: Semmelweisstrasse 7	Postal code: 82152	City: Planegg

 

2. Reason for notification (multiple reasons possible)   x Acquisition/disposal of shares with voting rights   ¨ Acquisition/disposal of instruments   ¨ Change of breakdown of voting rights   ¨ Other reason:

 

3. Details of person subject to the notification obligation
Natural person (first name, surname):         Date of birth:	Legal entity:   Novartis AG   City of registered office, country:   Lichtstrasse 35, 4056 Basel, Switzerland

 

4. Name(s) of shareholder(s) holding directly 3% or more voting rights, if different from 3. Novartis BidCo AG

 

5. Date on which threshold was crossed or reached: 23.05.2024

 

 

6. Total positions
	% of voting rights attached to shares (total of 7.a.)	% of voting rights through instruments (total of 7.b.1. + 7.b.2.)	Total of both in % (7.a. + 7.b.)	Total number of voting rights pursuant to Sec. 41 WpHG
New	79.46%	0.00%	0.00%	37,716,423
Previous notification	11.56%	0.00%	0.00%

 

7. Details on total positions
a. Voting rights attached to shares (Sec. 33, 34 WpHG)
ISIN	Absolute		In %
	Direct (Sec. 33 WpHG)	Indirect (Sec. 34 WpHG)	Direct (Sec. 33 WpHG)	Indirect (Sec. 34 WpHG)
DE0006632003	0	29,970,913	0.00%	79.46%
			%	%
Total	29,970,913		79.46%

 

b.1. Instruments according to Sec. 38 (1) no. 1 WpHG (please use annex in case of more than 3 instruments)
Type of instrument	Expiration or maturity date	Exercise or conversion period	Voting rights absolute	Voting rights in %
			0	0.00%
				%
				%
		Total	0	0.00%

 

b.2. Instruments according to Sec. 38 (1) no. 2 WpHG (please use annex in case of more than 3 instruments)
Type of instrument	Expiration or maturity date	Exercise or conversion period	Cash or physical settlement	Voting rights absolute	Voting rights in %
				0	0.00%
					%
					%
			Total	0	0.00%

 

 

8. Information in relation to the person subject to the notification obligation (please tick the applicable box):   ¨ Person subject to the notification (3.) obligation is not controlled nor does it control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer (1.).   x Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity (in case of more than four undertakings please always provide only to BaFin also an organizational chart):
Name	% of voting rights (if at least 3% or more)	% of voting rights through instruments (if at least 5% or more)	Total of both (if at least 5% or more)
Novartis AG	%	%	%
Novartis Pharma AG	%	%	%
Novartis BidCo AG	79.46%	%	79.46%

 

 

9. In case of proxy voting according to Sec. 34 (3) WpHG (only in case of attribution of voting rights in accordance with Sec. 34 (1) sent. 1 no. 6 WpHG) Date of general meeting: Total positions (6.) after general meeting:
% of voting rights attached to shares	% of voting rights through instruments	Total of both
%	%	%

 

10. Other useful information

 

 

Annex (only for BaFin) –

 

1. Identity of the person subject to the notification obligation:   Street:                   Lichtstrasse   Street number:    35   Postal code:        4056   City:                      Basel   Country:               Switzerland                                   In case of legal entities:       x   registered office         ¨  business address   Contact person:   David Quartner   Phone number:     +41 79 193 62 72   Fax number:   E-mail:                    david.quartner@novartis.com

 

2. Identity of notifier (if different from 1.)   Name:                    Dr. Rebecca Hettich   Company:             Freshfields Bruckhaus Deringer Rechtsanwälte Steuerberater PartG mbB   Street:                    Bockenheimer Anlage   Street number:     44   Postal code:         60322   City:                       Frankfurt am Main   Country:               Germany   Phone number:    +49 172 6643 834   Fax number:   E-mail:                   rebecca.hettich@freshfields.com

 

3. Other useful information:

 

 

---